Key Points
- Insider sale: Oruka Therapeutics SVP Arjun Agarwal sold 9,999 shares for approximately $805,919 at an average price of $80.60 under a pre-arranged Rule 10b5-1 plan. He retained 14,219 shares, with his ownership declining 41.29%.
- Stock and earnings: ORKA opened at $78.19, compared with a 52-week range of $24.88 to $115.51. The company reported quarterly EPS of $(0.55), missing the consensus estimate of $(0.51), and analysts expect a full-year EPS loss of $2.42.
- Analyst outlook: The stock has a “Moderate Buy” consensus rating from analysts, with a consensus price target of $128.91; ten analysts rate it Buy and one rates it Sell.
Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 9,999 shares of the firm's stock in a transaction on Monday, October 12th. The stock was sold at an average price of $80.60, for a total transaction of $805,919.40. Following the transaction, the senior vice president directly owned 14,219 shares in the company, valued at $1,146,051.40. The trade was a 41.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Arjun Agarwal also recently made the following trade(s):
- On Monday, September 21st, Arjun Agarwal sold 533 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.75, for a total transaction of $51,034.75.
- On Tuesday, September 15th, Arjun Agarwal sold 560 shares of Oruka Therapeutics stock. The shares were sold at an average price of $95.71, for a total transaction of $53,597.60.
- On Friday, September 11th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $92.23, for a total transaction of $872,403.57.
- On Thursday, August 13th, Arjun Agarwal sold 10,000 shares of Oruka Therapeutics stock. The stock was sold at an average price of $106.66, for a total transaction of $1,066,600.00.
Oruka Therapeutics Price Performance
NASDAQ ORKA opened at $78.19 on Wednesday. Oruka Therapeutics, Inc. has a 52-week low of $24.88 and a 52-week high of $115.51. The business's 50-day moving average price is $93.89 and its 200 day moving average price is $79.66.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, equities analysts forecast that Oruka Therapeutics, Inc. will post -2.42 EPS for the current year.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Mizuho set a $120.00 target price on Oruka Therapeutics in a research note on Thursday, September 3rd. Wedbush set a $120.00 price target on Oruka Therapeutics in a research note on Thursday, September 24th. Weiss Ratings raised Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 15th. UBS Group increased their price target on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a "buy" rating in a report on Wednesday, July 1st. Finally, Wall Street Zen lowered shares of Oruka Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, August 16th. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $128.91.
Read Our Latest Research Report on ORKA
Institutional Trading of Oruka Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in ORKA. Nykredit A S acquired a new position in Oruka Therapeutics during the second quarter worth $29,000. GAMMA Investing LLC raised its position in Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company's stock worth $31,000 after acquiring an additional 250 shares in the last quarter. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics in the second quarter valued at $91,000. Natural Investments LLC acquired a new stake in Oruka Therapeutics in the second quarter valued at $202,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Oruka Therapeutics in the fourth quarter valued at $67,000. Hedge funds and other institutional investors own 56.44% of the company's stock.
Oruka Therapeutics Company Profile
(
Get Free Report)
Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company's approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.
Oruka's pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
